Christian-H. Heeger: Does the CHAMPION AF Trial Signal a Potential Paradigm Shift in Stroke Prevention for AF?
Christian-H. Heeger, Head of the Department of Rhythmology at Asklepios Hamburg Altona, Professor of Electrophysiology at University of Lübeck, shared on LinkedIn:
”New evidence in stroke prevention for atrial fibrillation – a potential paradigm shift?
The CHAMPION AF trial is the first large randomized study evaluating the WATCHMAN FLX™ system as a first-line therapy compared to direct oral anticoagulants (DOACs).
Why does this matter?
DOACs remain the standard of care for stroke prevention in non-valvular atrial fibrillation.
However, long-term bleeding risk continues to be a major clinical concern.
Study overview (CHAMPION-AF):
- Randomized controlled trial with ~3,000 patients worldwide
- Comparison: Left atrial appendage closure (LAAC) vs. DOAC therapy
- Multi-year follow-up
Primary endpoints:
- Stroke, cardiovascular death, and systemic embolism (non-inferiority)
- Non-procedural bleeding (superiority)
Study objective:
To demonstrate that a one-time interventional approach can provide a safe and effective long-term alternative to chronic anticoagulation – even in patients without contraindications to oral anticoagulants.
What could this mean for clinical practice?
If confirmed, these findings could significantly expand the role of LAAC—potentially positioning it as an earlier treatment option in stroke prevention strategies for atrial fibrillation.
A highly anticipated study with the potential to reshape treatment pathways.
With Option and Champion patients after or during PVI will also benefit from this strategy!”
Stay updated with Hemostasis Today.
-
Oct 6, 2026, 03:13Patrick Taylor: Glow Stack Trend What the Evidence Really Shows
-
Oct 6, 2026, 02:59Preventing Hospital Associated Venous Thromboembolism – Thrombosis Canada
-
Oct 6, 2026, 02:42Treatment of Iron Deficiency With and Without Anemia – American Society of Hematology
-
Oct 6, 2026, 02:36Mouna Sassi: When Clinical and Laboratory Perspectives Meet in Thrombosis Care
-
Oct 6, 2026, 02:35Lucia Stefanini: Platelet Dysfunction and Oxidized Phospholipids in MASLD
-
Oct 6, 2026, 02:18Pablo Corral: Association of Lp(a) With Coronary Atherosclerosis and CV Events
-
Oct 5, 2026, 22:55Steve Humphreys: A Big Thank You to BSHT for Providing Me With a Recent Skills Exchange Award
-
Oct 5, 2026, 22:52William McKeown: Great to Be in Istanbul for the Opening of the EHC 2026
-
Oct 5, 2026, 22:48Laura Quintas Lorenzo: A New Approach to Healthcare for von Willebrand Disease at EHC 2026